Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240617 · ClinicalTrials.gov registry record · Phase 3
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
A Phase 3 study of Migraine Disorders, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
- 20
- Study locations
NCT00240617: Completed Phase 3 study of Migraine Disorders, sponsored by GlaxoSmithKline.
NCT00240617 is a Phase 3 study of Migraine Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 623 participants, above the 286-participant average among 21 other Migraine Disorders trials with a reported enrollment target (118% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240617, a Phase 3 study of Migraine Disorders, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
Conditions Studied
Interventions
- DRUG placebo
- DRUG sumatriptan succinate/naproxen sodium
Study Locations (20)
California
- GSK Investigational Site - Irvine
- GSK Investigational Site - Oceanside
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Pembroke Pines
- GSK Investigational Site - South Daytona
- GSK Investigational Site - Stuart
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Decatur
- GSK Investigational Site - Rome
Alabama
- GSK Investigational Site - Anniston
- GSK Investigational Site - Tuscaloosa
Arizona
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
Arkansas
- GSK Investigational Site - Hot Springs
Colorado
- GSK Investigational Site - Boulder
Connecticut
- GSK Investigational Site - Avon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00240617 record still lists
NCT00240617 is an interventional study that assigns participants to a tested intervention. The registered 623 participants enrollment target is mid-sized for trials with a published cap, above the 286-participant average among 21 other Migraine Disorders trials with a reported enrollment target (118% higher).
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00240617 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00240617 about?
NCT00240617 is a clinical study titled "Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks". The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
What is the current status of trial NCT00240617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2005-10. Estimated completion is 2006-06.
What conditions does trial NCT00240617 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT00240617?
The interventions under investigation include: placebo (DRUG), sumatriptan succinate/naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00240617?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00240617 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00240617's enrollment target sits among peer trials
623 4th of 21 higher than 18 of 21 other Migraine Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3 Study of MAP0004 in Adult Migraineurs
COMPLETED · Phase 3
-
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia